Jin Zhou is a Neurology physician. OpenAlex indexes 154 publications with 2,529 citations (h-index 19); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13620 Maple Ave # C705
Flushing, NY 113555166
Telephone
718-888-0316Provider last certified this registry record 25 Dec 2024.
Clinical trials
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
Sponsor: West China Hospital
- Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
Sponsor: West China Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments
- Axsome Therapeutics, Inc.Program year20253 payments
- Alexion Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
78.1%Cholinesterase Inhibitor19.5%Donepezil Hcl100%Part D≥139 patientsGabapentinoids19.4%Gabapentin94%Pregabalin6%Part D<11 patients+ 13 more classes in this area
Musculoskeletal
17.1%Nonsteroidal Anti-inflammatory Drug16.7%Diclofenac Sodium46%Diclofenac Epolamine40%Naproxen12%Naproxen-Esomeprazole Mag3%Part D<11 patientsgamma-Aminobutyric Acid-ergic Agonist0.4%Baclofen100%Part D<11 patientsCardiovascular
2.7%Beta blocker1.3%Propranolol Hcl100%Part D≥12 patientsAntiarrhythmic0.8%Lidocaine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of perceived rural destinations restorativeness on revisit intentions: The neglected post-travel negative emotions
Journal of Hospitality and Tourism Management
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”